TPST
$TPST
Tempest Therapeutics, Inc.
Clinical-stage biotech exploring cannabinoid-related therapeutics for oncology.
Cannabis$1.25
-0.01 (-0.79%)
Day Range$1.25 - $1.30
Prev Close$1.26
Analyst Rating
Strong Buy
6 Buy / 1 Hold / 0 Sell
Subscribers
0
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
This week's analysis
TPST: Dual-CAR T Acquisition, Clinical Catalysts
Tempest Therapeutics ($TPST) is a small-cap clinical-stage biotech with recent earnings beats and a strategic acquisition of dual-CAR T assets. Analysts are upbeat, but losses, dilution risk, and a collapsed share price leave the risk/reward mixed.
Apr 6, 2026